P. Knoblauch

发表

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

J. Plumb, J. D. de Bono, J. Tjørnelund, 2011, Cancer Chemotherapy and Pharmacology.

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

R. Advani, E. Jacobsen, L. F. Allen, 2015, British journal of haematology.

Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.

G. Giaccone, H. Mouridsen, H. Eidtmann, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.

K. Savage, P. Zinzani, S. Horwitz, 2013 .

APhase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced SolidTumors

Robert Brown, J. Plumb, N. Steele, 2008 .

belinostat In Relapsed Or Refractory Peripheral T-cell Lymphoma (r/r Ptcl) Subtype Angioimmunoblastic T-cell Lymphoma (aitl): Results From The Pivotal Belief Trial : 153

P. Zinzani, S. Horwitz, O. O’Connor, 2013 .

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

K. Savage, S. Horwitz, L. F. Allen, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas

Robin L. Jones, I. Judson, P. Rossen, 2016, Sarcoma.

A Phase I / II Clinical Trial of Belinostat ( PXD 101 ) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas

Robin L. Jones, I. Judson, P. Rossen, 2016 .

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

Robert Brown, J. Plumb, T. Evans, 2008, Clinical Cancer Research.

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

J. Bono, J. D. de Bono, S. Engelholm, 2010, British Journal of Cancer.

Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

J. Hainsworth, K. Fizazi, N. Penel, 2015, Cancer.

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

I. Christensen, L. Knudsen, P. Gimsing, 2008, European journal of haematology.

Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies

D. Petrylak, O. O’Connor, C. Diefenbach, 2011 .

Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies.

O. O’Connor, J. Bono, G. Blumenschein, 2010 .

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

J. Bono, S. Engelholm, R. Penson, 2010, British Journal of Cancer.